Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

brostallicin

Known as: 4-(2-Bromoacrylamido)-N'''-(2-guanidinoethyl)-1,1',1',1'''-tetramethyl-N,4':N',4':N',4'''-quater(pyrrole-2-carboxamide) 
A synthetic, alpha-bromoacrylic, second-generation minor groove binder (MGB), related to distamycin A, with potential antineoplastic activity… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
AIM Brostallicin is a DNA minor groove binder that has shown activity in patients with soft tissue sarcoma (STS) failing first… Expand
2010
2010
Brostallicin is a novel and unique glutathione transferase-activated pro-drug with promising anticancer activity, currently in… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2009
2009
Brostallicin (PNU-166196), a-bromo-acrylamido tetra-pyrrole derivative, showed high cytotoxic potency and myelotoxicity… Expand
2007
2007
The study aimed to assess the efficacy and safety of brostallicin, a new DNA minor groove binder, at a dose of 10mg/m2… Expand
Review
2004
Review
2004
Brostallicin is a bromoacryloyl derivative of distamycin A, which has shown very promising preclinical activity against a variety… Expand
2003
2003
Defects in DNA mismatch repair (MMR) are associated with a predisposition to tumorigenesis and with drug resistance owing to high… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
2003
2003
PURPOSE Brostallicin (PNU-166196) is a alpha-bromoacrylic DNA minor groove binder, currently in clinical evaluation. This drug… Expand
2003
2003
LC-MS-MS method using automated on-line solid-phase extraction (SPE) has been developed and validated for the quantitation of… Expand
Highly Cited
2002
Highly Cited
2002
Brostallicin (PNU-166196) is a synthetic alpha-bromoacrylic, second-generation DNA minor groove binder structurally related to… Expand
  • figure 1
  • table 1
  • table 2
  • table 4
  • figure 2
Review
2001
Review
2001
The relatively low therapeutic index of the clinically used alkylating agents is probably related to the fact that these… Expand